Fibromyalgia Therapies Show Limited Evidence of Pain and QOL Reduction
Oct 27, 2020
Recent News
-
JAMA Internal Medicine has published a review showing that most currently approved therapies for fibromyalgia (FM) do not have high-quality evidence to support their use; with some reducing pain or improving quality of life (QOL) in the short term, but overall effect size is not impressive.Read Article
Vedolizumab Promising in Immune-Related GI Events
Oct 27, 2020
Vedolizumab (Entyvio) was superior to infliximab (Remicade) for treating immune-mediated diarrhea and colitis (IMDC), a researcher reported.
In a retrospective study of patients with cancer, treatment with vedolizumab led to a 13% IMDC recurrence rate versus 28% with infliximab, according to Yinghong Wang, MD, PhD, of the MD Anderson Cancer Center in Houston.
Read Article
New research shows potential utility of plasma specialized pro-resolving mediator (SPM; like RvD4, 10S, 17S-diHDPA, 15R-LXA4 and MaR1n-3 DPA) concentrations as biomarkers to predict DMARD responsiveness in #RA. https://t.co/WQb57EON10
Dr. John Cush @RheumNow ( View Tweet)
Oct 27, 2020
Immune Necrotizing Myopathy
Oct 26, 2020
A full read review of immune-mediated necrotizing myopathy is portrayed as a distinct subtype of inflammatory myopathies first described in 2004.
Read Article
Telemedicine Outcomes in RA Care
Oct 26, 2020
A new short‐term follow‐up study has shown no significant difference in outcomes and quality measures in patients with RA who were managed by telemedicine (compared to usual in-person care).
Read Article
Review of 127 pts w/ diagnostic criteria for palindromic rheumatism - Most affected JTS were wrist, knee, MCP; 34% later developed CTD (28% RA, 2% lupus 3% other CTD). Progression predicted by +RF (HR 2.9), PIP (HR 2.4), Wrist (HR 2.5) & female (HR 2.2)
Dr. John Cush @RheumNow ( View Tweet)
Oct 26, 2020
Safety of nintedinib (NIN)in PSS-ILD - 576 PSS pts given NIN 150 mg bid or PBO x52wks. Dose lowered to 100 mg bid for AE. Diarrhea seen in 76% of NIN and 32% in PBO (d/c in 6.9% & 0.3%). Dose reduction in 48% & 12%.
Links:
Dr. John Cush @RheumNow ( View Tweet)
Oct 26, 2020
PI facts: did you know that JAK inhibitors(UPA, Bari, Tofa) have a warning against use w/ severe liver problems. They have not been studied in pts w/ Hepatitis B or C.
Links:
Dr. John Cush @RheumNow ( View Tweet)
Oct 26, 2020
Listent to QD Clinics - A Podcast Weekly Compilation - Lessons from the clinic. Dr.
Dr. John Cush @RheumNow ( View Tweet)
Oct 25, 2020
RheumNow Podcast is up!
Dr. John Cush @RheumNow ( View Tweet)
Oct 25, 2020
FDA Hearing on COVID-19 Vaccines
Oct 23, 2020
Yesterday the Food and Drug Administration's (FDA) "Vaccines and Related Biological Products Advisory Committee" convened a panel of experts to assess the development of vaccines for COVID-19 infection.
Read Article
RheumNow Podcast – Back Talk: Questions from Listeners (10.23.20)
Oct 23, 2020
Dr. Jack Cush reviews the news, journal reports, survey results and "Back Talk" questions from Rheums.
Read Article
Population study of 11 million, shows incidence of OPTIC NEURITIS is 3.7 /100K Pt-Yrs. Strongest association with multiple sclerosis (MS) and weaker associations with Behçet disease, sarcoidosis, and Sjögren syndrome. https://t.co/LVw0fcq1F1
Links:
Dr. John Cush @RheumNow ( View Tweet)
Oct 23, 2020
Randomized trial of 491 probable nonhospitalized COVID-19 pts shows that HCQ (given 800 mg, followed by 600 mg in 6 -8 hrs, then 600 mg qd x 4d) or placebo shows no reduction in symptom severity in outpatients with early, mild COVID-19.https://t.co/yVWGRr6jfr
Links:
Dr. John Cush @RheumNow ( View Tweet)
Oct 23, 2020
How are you consuming Virtual CME Rheumatology conferences
Dr. John Cush @RheumNow ( View Tweet)
Oct 23, 2020
Working on an Endocarditis for the Rheumatologist podcast. fast facts!!!
1️⃣ 20% no fever
2️⃣ 20% joint pain at presentation
3️⃣ >40% splenomegly
4️⃣ 90% anemia
5️⃣ most common rash = petechiae (Osler node/janeway/Roth spots 10% combined!)
#rheumatology #cleclinicrheum #immunology
Adam J Brown @AdamJBrownMD ( View Tweet)
Oct 23, 2020
High Burnout Rates Among Rheumatologists
Oct 22, 2020
Bergman and colleagues have studied a large cohort of US rheumatologists and found that nearly half meet at least one criterion defining "burnout" among physicians.
Read Article
Remdesivir FDA Approved for Hospitalized COVID-19
Oct 22, 2020
The FDA has approved Gilead Sciences Inc’s antiviral drug remdesivir for treating patients hospitalized with COVID-19, making it the first and only drug approved for the disease in the United States.
Read Article
FDA approved its 1st drug to treat COVID-19 - the antiviral drug Veklury (remdesivir) for for acute care treatment of COVID-19 requiring hospitalization. Approval based on 3 clinical trials showing clinical improvement, but no change in mortality rates.
Links:
Dr. John Cush @RheumNow ( View Tweet)
Oct 22, 2020
Study from China finds that hemophagocytic lymphohistiocytosis (HLH) was a rare (4.2%) but fatal (77.8%) complication in myositis patients (DM, PM, or CADM). Risk factors include baseline Dz activity, worsening ILD and infection https://t.co/QDN1DYzl5p
Links:
Dr. John Cush @RheumNow ( View Tweet)
Oct 22, 2020
How are you consuming Virtual CME Rheumatology conferences
Dr. John Cush @RheumNow ( View Tweet)
Oct 22, 2020
From the blog
Along with our patients, we've spent the last several months adapting to telemedicine. Following is an update on legislative changes and uncertainties, a look at the care gap that may still exist, and examining the trajectory of telemedicine after the initial rapid growth spurred by COVID-19.
Read Post
Recent Podcasts
QD102 - Undulating FeverOct 27, 2020-
QD101 - Episodic ArthritisOct 26, 2020
-
QD Videos98 - 100Oct 23, 2020
Therapeutic Update
BASDAI, ASDAS, ASAS, Oh My! Outcome Measures for Axial Spondyloarthritis
Sponsored by AbbVie US Medical Affairs
Oct 01, 2020
Patients with axial spondyloarthritis (axSpA) present with a wide range of symptoms. Given the disease’s heterogeneous presentation, what tools can be used to monitor patients with axSpA and their response to treatment? How can symptoms be tracked and analyzed over time? This article examines some commonly used axSpA disease measures, moving them from esoteric concepts to practical tools for understanding clinical trials and use in everyday practice.
Read Post
